Rapport Therapeutics, Inc. Common Stock
RAPP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $22 | $23 | $20 | $17 |
| G&A Expenses | $8 | $7 | $8 | $6 |
| SG&A Expenses | $8 | $7 | $8 | $6 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $30 | $29 | $27 | $24 |
| Operating Income | -$30 | -$29 | -$27 | -$24 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $3 | $3 | $3 | $4 |
| Pre-Tax Income | -$27 | -$27 | -$24 | -$20 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$27 | -$27 | -$24 | -$20 |
| % Margin | – | – | – | – |
| EPS | -0.71 | -0.75 | -0.12 | -0.1 |
| % Growth | 5.3% | -525% | -20% | – |
| EPS Diluted | -0.71 | -0.75 | -0.12 | -0.1 |
| Weighted Avg Shares Out | 379 | 354 | 193 | 193 |
| Weighted Avg Shares Out Dil | 379 | 354 | 193 | 193 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3 | $3 | $3 | $4 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$27 | -$29 | -$27 | -$23 |
| % Margin | – | – | – | – |